JPM2026: AI diagnostics and translational research, with Andrew Beck

2026-01-15

On-site on the sidelines of JP Morgan Healthcare conference in San Francisco this year, pharmaphorum editor-in-chief Jonah Comstock sat down with Andrew Beck, co-founder and CEO at PathAI. The conversation covers what PathAI has been up to lately in AI within diagnostics in pathology, explores what’s been discussed on the ground at the conference, and also touches upon equality and access to precision diagnostics. Additionally, Beck notes the company’s work in prospective clinical trials in ...

On-site on the sidelines of JP Morgan Healthcare conference in San Francisco this year, pharmaphorum editor-in-chief Jonah Comstock sat down with Andrew Beck, co-founder and CEO at PathAI.

The conversation covers what PathAI has been up to lately in AI within diagnostics in pathology, explores what’s been discussed on the ground at the conference, and also touches upon equality and access to precision diagnostics. Additionally, Beck notes the company’s work in prospective clinical trials in life sciences, as well as co-partnering with pharma.

Having seen an over 10 x growth of adoption of their technology in 2025, Beck also discusses advances in the MASH field.

Listen to this and other conversations from JPM2026 here.

You can listen to episode 240 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Comments (3)